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 A B S T R A C T 
Schizophrenia is a chronic mental disorder that is characterized by distracted mind, 
behavioral changes, including delusions and hallucinations. The incidence of 
schizophrenia is 1.25% of the 2.47% of the psychotic disorder population. 
Pharmacological therapy given to schizophrenia patient is antipsychotic agents that 
work on the brain neurotransmitters including dopamine, serotonin, and glutamate. 
Atypical antipsychotic agents are the first-line therapy for schizophrenia, whereas 
typical antipsychotics are used as the second line when there is no improvement in 
symptoms. However antipsychotics agents have frequent side effects such as 
weight gain and extrapyramidal symptoms. Other reported side effects are 
including increased prolactin level (sexual dysfunction and menstrual irregularity), 
cardiovascular system disturbance (hypotension and prolonged QT interval), and 
lipid changes (elevated triglyceride and cholesterol). Consequences of these side 
effects can lead to poor adherence of patients, disease progressiveness and increase 
of physical morbidity and mortality. This article uses 42 literatures with literature 
parameters used over the past ten years. The purpose of this article is to provide a 
concise review of schizophrenia and discusses the side effects of atypical and 
typical antipsychotics based on literature reviews. 
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1. Introduction 
Schizophrenia is one of the most frequent mental 
health problems to be encountered. According to the study 
by Chang et al. in 2017, the study  results showed that 
lifetime prevalence for schizophrenia is 1.25% of total 
psychotic disorder population.
1
 Schizophrenia disorder is 
characterized by positive symptoms (for instance, delusion, 
hallucination, uncontrolled mumbling), negative symptoms 
(such as withdrawal from social life and decreased life 
motivation) and cognitive impairments.
2
 Additionally, 




EugenBleuler created a term that is called 
“schizophrenia” in 1991. According to him, annual 
schizophrenia incidence was 15-20/100.000 with lifetime 
risk as many as 0.7%, and higher risk was found more in 
men than in women (1.4:1).
3
 Study in the United States 
with sample based on households showed  that prevalence 
of schizophrenia and other psychotic disorders ranged 
between 0.25% and 0.64%; while estimated prevalence of 
schizophrenia on non-institutionalized sample ranged 
between 0.33% and 0.75%.
4
 
Pharmacological therapy that was administered on 
schizophrenia patients was antipsychotic agents that 
targeted on the change in neurotransmitter in the brain such 
as dopamine, serotonin, norepinephrine, and glutamate. 
Antipsychotic agents that were used as the first line 
treatment is the atypical group, whereas typical 
antipsychotic agents were used if there is no improvement 
in symptoms. The most frequent side effects of 
antipsychotic agents including increased body weight and 
extrapyramidal syndrome. Other side effects that had also 
been reported including increased prolactin level (sexual 
dysfunction and irregular menstruation), cardiovascular 
system disturbance (hypotension and prolonged QT 
interval), and alteration of lipid level (increased 
triglyceride and cholesterol level). The impact of these side 
effects could lead to patients’ disobedience, the 






Clinical Limitations of Schizophrenia 
Schizophrenia is a complex mental disorder that 
could impact significantly to an individual and their 
family
2
. It is because schizophrenia is a chronic mental 
disorder that could lead the patient to have a distracted 
mind, including delusion and hallucination. Additionally, 
patients often difficult to differentiate between reality and 
their minds.
3,6,7




a. Paranoid schizophrenia, the most common 
schizophrenia, in which delusion and auditory 
hallucination are evident. 
b. Catatonic schizophrenia, which is less frequent 
type (about 7% cases). Typical symptoms 
include psychomotor disorder, catatonic, change 
of behaviour, echolalia (repetition of speech) 
and echopraxia (repetition of action). 
c. Hebephrenic schizophrenia (unorganized), 
which is early onset of schizophrenia followed 
by a bad prognosis. Irresponsivebehaviour and 
unpredictable; influenced by inappropriate 
mood, including exaggerated laugh, 
inappropriate behaviour and joke are symptoms 
that can reveal. Additionally, this subtype is 
often accompanied by delusion and 
hallucination. 
d. Residual Schizophrenia (chronic), which is 
schizophrenia with a history of one of 
schizophrenia that has been explained above, yet 
the disorder is currently showing “negative” 
symptoms and often dominated by cognitive 
symptoms. 
e. Simple schizophrenia, is uncommon 
schizophrenia; whereas negative symptom 
without exhibit psychotic trait. 
Etiopathophysiology of Schizophrenia 




Studies showed that schizophrenia is caused by 
family inheritance (genetic). Relative risk of 
schizophrenia inheritance from first line 
biological family is 10%. If both parents have 
schizophrenia, then the risk to be schizophrenia 
on their child will be 40%. Schizophrenia 
concordance is 10% for dizygotic twins and 40-
50% on monozygotic twins.
7
 
b. Neurochemical alteration 
Some neurotransmitters have been associated 
with this disorder. Dopamine, serotonin, 
norepinephrine, GABA, and glutamate are some 
neurotransmitters that have shown involvement 
in schizophrenia pathogenesis (Figure 1).
7,8
 
Figure 1a explains about glutamatergic, 
GABAergic, and dopaminergic from cortical area and 
substantianigra to accumbens nucleus and striatum, and 
hippocampus. Whereas figure 1b reveals about the effects 
of NMDA antagonist receptor on this cortex; reduced 
GABAergic innervations, reduced tonic dopamine and 
increased of phasic dopamine release in the striatum. 
Dopamine role is based on two dopamine 
hypotheses. First, there is a group of agents that block 
dopamine function, known as phenothiazine and could 
reduce psychotic symptoms. Second, amphetamine, which 
increases dopamine release inducing paranoid psychotic 
and aggravate schizophrenia, and disulfiram that inhibits 




Glutamate role in schizophrenia is majorly based on 
a hypothesis that glutamate reduces the function of NMDA 
glutamate receptors involved in schizophrenia 
pathophysiology. Besides, excessive serotonin could lead 
to the positive and negative symptoms of schizophrenia. 
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Norepinephrine as a neurotransmitter could also be 
included to cause schizophrenia. Selective neural 
degeneration in norepinephrine reward system explains 
anhedonia that occurs in schizophrenia patient. Other 
neurotransmitters that are involved in the occurrence of 
schizophrenia are G-Aminobutyric Acid (GABA) which 
has a regulation effect on dopamine activity and the loss of 
inhibitory GABAergic neurons could lead to the 






















Figure 1. Role of Dopamine, Glutamate, GABA in Schizophrenia 
Pathogenesis8 
Disorder in neurotransmission has yielded 
fundamental of pathophysiology theory of schizophrenia. 
This theory mainly focused on excessive or deficiency of 
neurotransmitters in the brain including dopamine, 
serotonin, norepinephrine, and glutamate. Other theories 
stated that the pathophysiology of schizophrenia involves 
aspartate, glycine, and gamma-aminobutyric acid as part of 
the neurochemical imbalance in schizophrenia.
6
 
Abnormal activities on dopamine receptor 
particularly D2 dopamine receptor is suspected to be 
associated in many of schizophrenia symptoms. Four 
dopaminergic pathways have been implicated (see Figure 
2). The first pathway is the nigrostriatal pathway that is 
originated from substantianigra and ended in the caudate 
nucleus. Low dopamine level in this pathway is considered 
affecting the extrapyramidal system that leads to motoric 
symptoms. The second pathway is the mesolimbic pathway 
that spread from ventral tegmental area (VTA) to limbic 
area, also has a role in the positive symptom of 
schizophrenia to excessive dopamine level. The third 
pathway is the mesocortical pathway which is spread from 
the VTA to the cortex. Negative symptoms and cognitive 
deficits in schizophrenia are suggested to be caused by low 
mesocortical dopamine level. The fourth pathway is the 
tuberoinfundibular pathway from the hypothalamus to the 
pituitary gland, where decreased or blockade on 
tuberoinfundibular dopamine increases prolactin and as a 




Therapeutic Management of Schizophrenia 
The therapy used to treat schizophrenia is an 
antipsychotic agents. Antipsychotic agents are very 
effective to treat any positive symptoms in acute episodes 
including hallucination, delusion, and also very useful to 
prevent relapse. Antipsychotic therapy algorithm for 
schizophrenia is shown in Figure 3.
10
 
Antipsychotic consisted of 2 groups including 
typical antipsychotic agents (conventional/first generation) 
and atypical antipsychotic agents (second generation). 
Antipsychotic grouping is shown in Table 1.
3,7
 
Table 1. Atypical and Typical Antipsychotics3 




Clozapine Phenothiazines Chlorpromazine, 
Risperidone  Fluphenazine, 
Quetiapine  Trifuoperazine 
Olanzapine Butyrophenones Haloperidol 
Aripiprazole Thioxanthenes Flupentixol, 
Ziprasidone  Zuclopenthixol 
Amisulpride Diphenylbutylpiperidines Pimozide 
Paliperidone Substituted benzamides Sulpiride 
Side Effects of Antipsychotic & Therapy Management 
Atypical group of antipsychotic agents has a lot 
more metabolic side effects such as increased body weight, 
cardiac arrhythmia, hyperlipidemia, and diabetes which is 
caused by insulin resistance; whereas typical group of 
antipsychotic agents has more significant side effects such 
as extrapyramidal syndromes (EPS), hyperprolactinemia, 
and tardive dyskinesia, because of stronger dopaminergic 
effects of the these agents.
9,3,12,5,10 
Table 2 shows a 
comparation among the side effects of typical and atypical 
group of antipsychotic agents in causing body weight and 
extrapyramidal syndromes.Side effect comparison among 
antipsychotic agents, FGA (first-generation antipsychotics) 
and SGA (second-generation antipsychotics), is showed on 
Table 3. Prevalence side effects in the first and second 
generation of antipsychotic drug that occurred in Indonesia 
is shown on Table 4.  
Side Effects of Antipsychotic Agents on Endocrine 
System 
Hyperprolactinemia has been reported up to 87% patients 
that were administered with antipsychotic agents including 
risperidone, haloperidol, and 
paliperidone.
9,16,6,17
Hyperprolactinemia is clinically defined 
as plasma prolactin level > 20 ng/ml for male and > 25 
ng/ml for female. Hyperprolactinemia could lead to sexual 
dysfunction,anddecrease libido, cause irregular 
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menstruation and gynecomastia.
18,19
It is suggested that 























Figure 2. Pathophysiology of Schizophrenia5 
caused by antipsychotic agents that block D2 dopamine 
receptor in tuberoinfundibular thus remove inhibition of 
prolactin secretion and increase prolactin plasma level. 
Aripiprazole or ziprasidone is preferred for patients with 
increased prolactin level because this antipsychotic agent 
has a relatively low sexual dysfunction compared to some 
antipsychotic agents including clozapine, olanzapine, 
risperidone, and other conventional antipsychotic 
agents.
22,23,17 
Therapeutic management to resolve sexual 
dysfunction side effects is by using dopamine agonist 
(e.g.bromocriptine and cabergoline) and by using 
dopamine release agents such as amantadine, although the 
usage of the agents needs further study. Additionally, these 
side effects could also be done by sildenafil therapy. Then, 
recent study showed that more erection that was enough to 




According to study by Takachiet al. in 2017, a 
study of 83 women, mean prolactin serum level was higher 
in patients with irregular menstruation than patients 
without menstruation disorder (89.3 ± 36.9 vs 42.5 ± 54.5; 
95% confidence interval (CI): 46.8 [19.3 – 74.3]).
25
How 
antipsychotics promote menstruation disorder or stopped 
menstruation is not fully elucidated.However, dopamine 
blockade induced hyperprolactinemia is believed to 
become a major cause. Increased prolactin level promotes 
hormonal disorder that releases gonadotropin, which in the 
end causes irregular menstruation and amenorrhea.
26
 
Increased body weight is another significant side 
effect on patients with antipsychotic agents. This side 
effect remains to happen in the early therapy of 
schizophrenia patients with antipsychotic agents and could 
lead to patient disobedience to consume their antipsychotic 
agents. Then, these antipsychotic agents could promote 
some side effects that have been related to increased risk of 
diabetes mellitus and cardiovascular and cerebrovascular 
mortality.
8,5,27
 Clozapine and olanzapine have shown to 
have the biggest risk of increasing body weight and the 
highest risk of diabetes mellitus, followed by risperidone 
and quetiapine. However, risperidone and quetiapine had a 
minimal risk in increasing body weight.
9,12,28,6,29
 
Table 2. Side Effects Comparison Between Typical and Atypical 
Antipsychotic in Causing Body Weight and Extrapyramidal Syndromes5 
Drug Weight Gain Extrapyramidal 
Syndromes 
Typical Antipsychotics (First-generation Antipsychotics)  
Chlorpromazine 
(Thorazine) 
+ + + + + 
Fluphenazine (Prolixin) + + + + + 
Haoperidol (Haldol) + + + + + 
Perphenazine 
(Trilafon) 
+ + + + + 
Thioridazine (Mellaril) + + + + 
Thiothixene (Navane) +  + + + + 
Atypical Antipsychotics (Second-Generation Antipsychotics) 
Aripiprazole (Abilify) + + 
Anesapine (Saphris) + + + 
Clozapine (Clozaril) + + + + +  
Iloperidone (Fanapt) + + ± 
Lurasidone (Latuda) ± + 
Olanzapine (Zyprexa) + + + + + + 
Paliperidone (Invega) + + + + 
Quetiapine (Seroquel) + + + 
Risperidone 
(Risperdal) 
+ + + + 
Ziprasidone (Geodon) + + + 
± = negligible risk;  
+ = low risk;  
+ + = moderate risk;  
+ + + = moderately high risk; 
+ + + + = high risk 
 Prevalence of metabolic syndrome in 
schizophrenia is exceptionally high, supported by a meta-
analysis of 77 publications that reported the prevalence was 
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as high as 32,5% (95% CI = 30,1-35%). Based on Adult 
Treatment Panel III of the National Cholesterol Education 
Program Criteria estimated that this worrying proportion as 
many as 49,4% was obese.
27
 This side effect, increased 
body weight, has been associated with the antipsychotic 
mechanism of action on 5-HT2A and 5-HT2C serotonin, 
dopamine D2 and D3, H1 Histamine and M3 muscarinic 
receptors. Antipsychotic agents also affect neuropeptide 
that controls appetite and energy metabolism. Other 
mechanisms that involve in increasing body weight are 
increased leptin level and reduced adiponectin level that 
was produced in adipose tissue, and alteration ghrelin level 
which acts on the arcuate nucleus of the hypothalamus to 
increase appetite and adipose tissue deposition.
29,27
 
Therapeutic management to overcome this 
increasing body weight as a comorbid of diabetes, can be 
considered by administering metformin therapy. There is 
convincing evidence that supported metformin use in 
antipsychotic side effects management on increasing body 






























Figure 3. Antipsychotic Therapeutic Algorithm for Schizophrenia10 
Side Effects of Antipsychotic Agents on Central 
Nervous System 
The main extrapyramidal syndromes that are 
caused by antipsychotic agents are acute dystonia, 
akathisia, pseudoparkinsonism, and tardive 
dyskinesia.
32
These symptoms could lead to inconvenience, 
social stigma, and disobedience for patients. Dystonia often 
leads to disobedience and could threat patient’s life. A 
dystonic reaction usually occurred in patients that were 
treated with FGA (first generation antipsychotics/typical) 
and often seen in the younger male. Dystonia can be 
minimalized by using SGA (second generation of 




Akathisiaincludes 50% of extrapyramidal 
syndrome. Akathisia often concurred with dysphoria, 
which was seen 20% up to 40% patients that were treated 
with high potent FGA such as haloperidol and 
fluphenazine; whereasquetiapine and clozapine are seemed 
to have the lowest akathisia side effect. Based on a study 
that was conducted in McGann District Care Teaching 
Hospital, ShivamoggaInstitue of Medical Science, 
prevalence of akathisia is 10% to 20% in patients with 
atypical antipsychotic therapy; whereas patients with 
typical antipsychotic therapy with akathisia are about 20% 
to 52% [33%]. 
Pseudoparkinsonsism is another side effect which 
is occurred in patients that were treated with antipsychotic 
therapy FGA mostly seen in women and geriatric patient 
15% and 36%, respectively. The mechanism of this 
antipsychotic side effect on parkinsonism is 
neurotransmitter imbalance such as hypoactivity of the D2 
dopaminergic neuron, GABA, and acetylcholine, and 
hyperactivity of muscarinic cholinergic neuron M4.
34
 
Hypoactivity of dopamine occurs after 
administration of FGA and SGA therapy. Dopaminergic 
Stage 1A 
Treatment-naïve individual with first break 
schizophrenia 
. . . 




Previously treated with an antipsychotic for schizophrenia, and 
treatment is being restarted. 
. . . 
Any antipsychotic except clozapine. An antipsychotic that 




Patient had inadequate clinical response with 
antipsychotic used in stage 1A or 1B 
. . .  
Any antipsychotic monotherapy, except 
clozapine, not used in stage 1A or 1B. Many 
consider clozapine in severe suicidal patient. 
Stage 3 
Patient has had inadequate clinical response 
with two appropriate antipsychotic trials 
. . .  
Clozapine monotherapy is recommended 
Use a long-acting injectable 
antipsychotic at either stage 2 
or 4 if needed for poor patient 
adherence or because of 
patient preference 
Stage 4 
Minimal evidence exists for treatment options 
for patients who have not received an adequate 
treatment response with clozapine. 
Alternate antipsychotic monotherapy may be as 
good as augmentation or antipsychotic 
combinations 
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neurons on substansianigra activate D1 dan D2 
dopaminergic neurons in the caudate nucleus. In the 
nucleus, D1 dopaminergic neuron weakly 
activatedynorphin neurons; while D2 dopaminergic 
neurons activate GABAergic neurons






















+ + + + 0 + + + + + 0 0 
Dyslipidemia + + + 0 + + + + + + + + + 0 
Extrapyramidal 
symptoms 
+ + + + + 0 + 0 + + + 




+ + + + + + + + + 
Postural 
hypotention 
+ + + + + + + + + + +  + + + 
Prolonged QT 
interval 
+ + c + + + + + + + + 
Sedation + + + + + + + + + + + + + + 
Seizures + + + + + + + + + + 
Sexual dysfunction + + + + + + + + + + + + 
Type 2 Diabetes 
Mellitus 
+ + + + + + + + + + 
Weight Gain + + + 0 + + + + + + + + + + 0 
Note : 0 = rare; + = lower risk; + + = medium risk; + + + = higher risk. 
FGAs = first-generation antipsychotics; SGAs = second-generation antipsychotics. 
* --- Effect are approximate, and relative to other antipsychotic medications rather than absolute risk of an adverse effects occuminng. 
a --- FGAs with lower potency dopamine D2 neuroreceptor blockade, including chlorpromazine and thioridazine. 
b --- FGAs with higher potency dopamine D2 neuroreceptor blockade. These include fluphenazine, haloperidol (formely haldol), thiothixene (Navane), and 
influoperazine. Please note that the FGA perphenazine is considered to have intermediate dopamine D2 neuroreceptor blockade, with an adverse effect 
profile between the low and high-potency FGAs. 
c --- individually, thioridazine has a higher risk of prolonged QT interval and should be used only when no other appropriate options are available. 
 
Adapted with permission from Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic agents : a critical overview. CMAJ. 2005; 172(13):1703-
1711, with additional information from reference 6. 
 
 
in external globuspallidus. In internal globuspallidus, M4 
muscarinic cholinergic neurons which are located in the 
putamen can increase hyperactivity of acetylcholine. In 
putamen, there is antagonist interaction between D2 
dopaminergic neurons and 5-HT2A serotonin neurons by 
glutamatergic neurons that inhibit presynaptic NMDA. 
Thus, SGA with the antagonist effect of 5-HT2A in lower 
level could promote extrapyramidal syndrome.
34
 
Tardive dyskinesia risk ranged between 0.5% and 
62%. This side effect occurred in patients that were treated 
with long-term typical group antipsychotic therapy and the 
risk continued to increase in older patients. Risk of tardive 
dyskinesia significantly lower in patients with atypical 
group antipsychotic therapy and no case to be reported in 
patients treated with clozapinemonotherapy. This is 
because antipsychotic agents such as chlorpromazine, 
thioridazine, mesoridazine, clozapine, olanzapine, and 
quetiapine have been reported to be the highest sedation 
potential.
9,6 
Neuroleptic Malignant Syndrome (NMS) is a rare 
side effect of antipsychotic therapy, but it is a life-
threatening condition. This side effect is found about 0.5% 
to 1.0% in patients that are treated with FGA therapy. 
Mental side effects such as psychosis and delirium could 
also be found in patients with FGA therapy with higher 
dose or patients with combination therapy with 
anticholinergic.
6
Therapy management to treat 
extrapyramidal side effects, that are often occurred, is 
showed on Table 6. 
 
Side Effects of Antipsychotic Agents on Cardiovascular 
System 
Orthostatic hypotension has been occurred up to 75% of 
patients with antipsychotic therapy. 
Tabel 4. Prevalence of Side effects of Antipsychotic Agents in 
Indonesia13,14,15 




Mental Hospital, South 
Kalimantan14 
In the Hospital 























Sedation (44,1%)  
 Nausea (27,1%)  
 Insomnia (16,9%)  
 Anorexia (5,1%)  
 Shortness of breath and 
cough (1,7%) 
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Patients with diabetes mellitus, with the previous 
history of cardiovascular disease, or elder patients had the 
greatest risk of orthostatic hypotension.
9,6
 Orthostatic 
hypotension is defined as decreased blood pressure (>20/10 
mmHg) in 3 minutes on standing position. The 
antipsychotic agent that frequently causes orthostatic 
hypotension side effect is aripiprazole. However, some 
studies implied that orthostatic hypotension was caused by 
aripiprazole and clozapine. This side effect was mainly 
because aripiprazole and clozapine were competitive to α1 
adrenoreceptor, thus promote a higher risk of orthostatic 
hypotension. As a 5-HT2A antagonist and 5-HT1A partial 




Table 5. Metformin Therapy to Overcome Increasing Body Weight 30,31,29. 
Characteristics Studies 
Wu et al (2012) Wang et al (2012) 
Arms Metformin 1g/day vs 
placebo 
Metformin 1g/day vs 
placebo 
Trial duration 6 months 12 weeks 
No. of patients 
(completers/total) 
76/84 66/72 
Primary outcome Restoration of 
menstruation. 
Change in weight and 
BMI. 




















This orthostatic hypotension side effect could be 
resolved by administrating fludrocortisone or ephedrine 
therapy if non-pharmacology therapies were failed. 
However, this administration should be done with caution 
because of the side effects. If there was still severe and 
refractory hypotension, it should be considered to cease 
clozapine therapy by stepping down the dose gradually in 2 
weeks to prevent any cholinergic rebound and to switch 
into other alternative antipsychotics.
37
 
Alteration in electrocardiography, particularly 
prolonged QTc could be found in a few patients with 
antipsychotic agents such as thioridazine, ziprasidone, 
risperidone, clozapine, olanzapine, and haloperidol.
38
 
Widened or prolonged QTc must be monitored during 
therapy, and antipsychotic agents must be ceased if this 
interval consistently surpassed 500 msec. Patients with a 
history of cardiac or cerebrovascular diseases, also patients 
in diuretic therapy, should take antipsychotic with caution 
because the risk of prolonged QTc interval.
9,6 
Side Effects of Antipsychotic Agents on Alteration of 
Lipid Profile 
Patients treated with atypical antipsychotic 
therapy such as phenothiazine tended to show increasing 
triglyceride and cholesterol level. Atypical antipsychotic 
agents that showed a low risk of lipid alteration were 
risperidone, ziprasidone, and aripiprazole.
9,6
 Antipsychotic 
effects on lipid alteration had been associated with 
increased triglyceride and very low-density lipoprotein 
release from adiposity. Additionally, antipsychotic could 
promote expression of sterol regulatory element-binding 




Sterol regulatory element-binding proteins 
(SREBPs) were the centres to control allosteric from any 
lipid biosynthesis pathway. Notably, SREBP-1 was 
responsible as metabolism controller of triglyceride and 





Table 6. Therapy to Treat Extrapyramidal Side Effects35 
Side effect Prevention Treatment 
Acute dystonic 
reactions 
* Select antipsychotic 
with low rate EPS 
* Oral or intravenous 
application of 
anticholinergic drug, 
e.g., 2,5-5 mg biperien, 
if necessary repeat 
procedure after 30 min, 
continue with 
biperiden oral 
(maximal 12 mg/d). 
 
* Start with low dose 
* Increase dose slowly 
and stepwise 
Parkinsonism * Select antipsychotic 
with low risk for 
parkinsonism 




* Increase dose slowly 
and stepwise 
* Switch to SGA 
* Oral application of 
anticholinergic drug 
 
Akathisia * Select antipsychotic 
with low risk for 
akathisia 
* Dose reduction 
* Increase dose slowly 
and stepwise 
* Oral application of 
beta-receptor blocking 
agent (e.g., propanolol 
30-90 mg/dl) 
* Switch to certain 
SGAs 
* Oral application of 
benzodiazepines 
* Trial of an 
anticholinergic or an 
antihistaminic agent 
* Application of 
vitamin B6 





* Select antipsychotic 
with low risk for 
tardive dyskinesia 
* Switch to cozapine 
(alternatively to certain 
other SGAs) 
* Evaluate risk factors 
for tardive dyskinesia 
* Administration of 
vitamin E 
* (Adminitration of 
tiapride) 
* ECT (only case 
reports and case series) 
* Deep brain 
stimulation (treatment 
in severe cases) 
* Pallidotomy (last 







* Select antipsychotics 
with low risk for NMS 
* Intensive care 
management 
* Stop antipsychotic 
treatment 
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* (Application of 
dantrolene I.V (2,5-10 
mg/kg body weight 
daily) 
* (Application of 
lorazepam 4-8 mg 
I.V/d). 
* In single cases ECT 
In the liver, excessive SREBP activity could lead to 
increased circulation of cholesterol, free fatty acid (FFA), 
and triacylglycerol. Olanzapine, clozapine, and risperidone 
could promote significant upregulation of SREBP-1 and 
SREBP-2, and their downstream target genes that directed 
to increased lipid and cholesterol synthesis. Even single 
intraperitoneal injection with clozapine and olanzapine 
could induce increased FFA serum, followed by hepatic 
lipid accumulation.
40 
Monitoring Side Effects of Antipsychotic Agents 
While on therapy with antipsychotic agents, patients 
must regularly be monitored by recording therapy 
effectivity, the side effect of agents, adherence, and 
physical health of the patients. Besides, they also should be 
monitored periodically for body weight, lipid and glucose 
profile, and ECG.
3
 Guideline to prevent and monitor 
metabolic alteration side effect on patients with 




Table 7. Monitoring Side Effect of SGA on Metabolic Alteration9,42,35 
Assessment 
parameter 
Baseline 4 weeks 8 weeks 12 weeks Quarterly Annualy Every 5 
years 




x     x  
Weight (body mass 
index) 
x x x x x   
Waist 
circumference 
x     x  
Blood pressure x   x  x  
Fasting plasma 
glucose level 
x   x  x  
Fasting lipid 
profile 
x   x   x 
 
X = more frequent assessments may be warranted based on clinical status 
 
Reprinted with permission from American Diabetes Association; American Psychiatric Association; American Association of 
Clinical Endrocrinologists; North American Association for the Study of Obesity. Consensus development conference on 
antipsychotic agents and obesity and diabetes. Diabetes Care. 2004;27(2):599. 
 
3. CONCLUSION 
Antipsychotic therapy in schizophrenic patients has 
side effects such as: 
1. Extrapyramidal syndrome. This is caused by 
imbalance of neurotransmitters such as 
hypoactivity of the D2 dopaminergic neuron, 
GABA, and acetylcholine, and hyperactivity of 
muscarinic cholinergic neuron M4. 
2. Weight gain. This is related to the action of 
antipsychotics on 5-HT2A and 5-HT2C serotonin, 
dopamine D2 and D3, H1 Histamine and M3 
muscarinic receptor, increased body weight 
including increased leptin level, reduced 
adiponectin level, and alteration in ghrelin level. 
3. Sexual dysfunction, decreased libido, irregular 
menstruation, and gynecomastia due to 
hyperprolactinemia. This side effects are caused 
by antipsychotic agents that block D2 dopamine 
receptor in tuberoinfundibular thus remove 
inhibition of prolactin secretion and increase 
prolactin plasma level. 
4. Orthostatic hypotension. This is because 
antipsychotics were competitive to α1 
adrenoreceptor. Antipsychotics that work as 5-
HT2A antagonists and 5-HT1A partial agonists 
can increase the risk of orthostatic hypotension. 
5. Increased level of triglyceride and cholesterol. 
This relates to increasing triglyceride, sterol 
regulatory element-binding proteins (SREBP) and 
very low-density lipoprotein (VLDL) genes. 
The impact of these side effects could lead to 
discomfort and patient disobedience, the progressiveness of 
other diseases and increased physical morbidity and 
mortality. Therefore, it is very important to monitor side 
effects in schizophrenia patients treated with 
antipsychotics. 
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